Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) EPS (Weighted Average and Diluted) (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.12 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 70.0% year-over-year to -$0.12; the TTM value through Dec 2025 reached -$1.84, down 38.35%, while the annual FY2025 figure was -$1.84, 40.46% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.12 in Q4 2025 per TLSI's latest filing, up from -$1.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $30.69 in Q3 2023 and bottomed at -$161.74 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$12.34, with a median of -$0.4 recorded in 2024.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 218.27% in 2023, down 44900.0% in 2023.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$161.74 in 2022, then skyrocketed by 99.35% to -$1.05 in 2023, then soared by 61.9% to -$0.4 in 2024, then skyrocketed by 70.0% to -$0.12 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.12 in Q4 2025, -$1.07 in Q3 2025, and -$0.26 in Q2 2025.